GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gennex Laboratories Ltd (BOM:531739) » Definitions » LT-Debt-to-Total-Asset

Gennex Laboratories (BOM:531739) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Gennex Laboratories LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Gennex Laboratories's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Gennex Laboratories's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).


Gennex Laboratories LT-Debt-to-Total-Asset Historical Data

The historical data trend for Gennex Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gennex Laboratories LT-Debt-to-Total-Asset Chart

Gennex Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.12 0.06

Gennex Laboratories Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.06 - 0.07 -

Gennex Laboratories LT-Debt-to-Total-Asset Calculation

Gennex Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )/Total Assets (A: Mar. 2024 )
=132.164/2299.858
=0.06

Gennex Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=0/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gennex Laboratories  (BOM:531739) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Gennex Laboratories LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Gennex Laboratories's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Gennex Laboratories Business Description

Traded in Other Exchanges
N/A
Address
Akash Ganga, Plot No. 144, 4th Floor, Srinagar Colony, Hyderabad, TG, IND, 500 073
Gennex Laboratories Ltd is engaged in the manufacturing of bulk drugs, and intermediates, Biotech Products. Geographically, the group has a business presence in Bangladesh, Egypt, Germany, Guatemala, Iran, Israel and other countries. Its products include Guaifenesin, Methocarbamol, Fluconazole and Phenazopyridine, among others.

Gennex Laboratories Headlines

No Headlines